Cerebral venous sinus thrombosis cases detected in on-call CT venographies in Sweden, 2019-2022.
COVID-19
CT
Cerebral vein sinus thrombosis
Postpartum
Pregnancy
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
06
08
2023
medline:
5
10
2023
pubmed:
20
8
2023
entrez:
20
8
2023
Statut:
ppublish
Résumé
No well-established criteria exist for assessing the risk of cerebral venous sinus thrombosis (CVST). Here, we sought to gain an understanding of CVST cases and associated risk factors, based on the rates of emergency CT venographies (CTVs) performed after hours. Furthermore, we aimed to assess possible correlations between CVST rates and COVID-19, including at the start of the COVID-19 vaccination campaign. We collected reports of emergency CTVs performed after hours at 56 Swedish hospitals between 1/1/2019 and 12/31/2022, and divided them into five groups: (I) from 1/1/2019 to 1/31/2020, before the emergence of COVID-19 cases in Sweden; (II) from 2/1/2020 to 12/26/2020, after the emergence of COVID-19 but before vaccination rollout; (III) from 12/27/2020 to 7/28/2021, from the start of the COVID-19 vaccination campaign until 50% of the adult population in Sweden had been vaccinated; (IV) from 7/29/2021 to 2/1/2022, from when 50% of the adult population was vaccinated until restrictions were lifted; and (V) from 2/2/2022 to 12/31/2022, after restriction measures were suspended. For all included patients, we collected information on demographics and clinical history, including pregnancy, recent partum, and use of oral contraceptives or post-menopausal hormone replacement therapy. In total, we collected 430 reports (92% female, 8% male). The CVST positivity rate was 22.2% in men vs. 2.3% in women. None of the pregnant (n = 49) or postpartum (n = 12) women had CVST positivity. The frequency of CTV examinations was lowest in group 2; during this period, the average time between patients being imaged was 7 days. The frequency of CTV examinations was highest in group IV; during this period, a patient underwent this type of scan every 1.5 days, on average. The frequency of CVST-positive scans was lowest in group II; during this period, a positive case was found every 66 days, on average. The frequency of CVST-positive scans was highest in group IV; during this period, a positive case was found every 62 days, on average, and no statistical difference with respect to group II was observed. Pregnancy and recent partum were not significant risk factors for CVST. The elevated CVST positivity rate observed during the height of the COVID-19 pandemic suggested that patients with less likelihood for positive CVST had fewer emergency visits. The positivity rate did not increase with the start of the COVID-19 pandemic or the rollout of COVID-19 vaccination.
Identifiants
pubmed: 37598388
doi: 10.1007/s11239-023-02883-x
pii: 10.1007/s11239-023-02883-x
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
548-554Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F (2004) ISCVT investigators: prognosis of cerebral vein and Dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35(3):664–670. https://doi.org/10.1161/01.STR.0000117571.76197.26
doi: 10.1161/01.STR.0000117571.76197.26
pubmed: 14976332
de Freitas GR, Bogousslavsky J (2008) Risk factors of cerebral vein and sinus thrombosis. Front Neurol Neurosci 23:23–54. https://doi.org/10.1159/000111259 . (PMID: 18004052)
doi: 10.1159/000111259
pubmed: 18004052
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.013
doi: 10.1016/j.thromres.2020.04.013
pubmed: 32291094
pmcid: 7146714
Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, Muscarella G, Orlandi M (2020) Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 120(8):1230–1232. https://doi.org/10.1055/s-0040-1712097
doi: 10.1055/s-0040-1712097
pubmed: 32349132
pmcid: 7516356
Mowla A, Shakibajahromi B, Shahjouei S, Borhani-Haghighi A, Rahimian N, Baharvahdat H, Naderi S, Khorvash F, Altafi D, Ebrahimzadeh SA, Farahmand G, Vaghefi Far A, Sharma VK, Neshin SAS, Tsivgoulis G, Zand R (2020) Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series. J Neurol Sci. 419:117183. https://doi.org/10.1016/j.jns.2020.117183
doi: 10.1016/j.jns.2020.117183
pubmed: 33075595
pmcid: 7556283
Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A (2021) Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 428:117607. https://doi.org/10.1016/j.jns.2021.117607
doi: 10.1016/j.jns.2021.117607
pubmed: 34365148
pmcid: 8330139
Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, Petzold GC, Piccininni M, Poli S, Röhrig R, Steinmetz H, Thiele T, Kurth T (2021) German society of neurology SARS-CoV-2 vaccination study group: COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol 90(4):627–639. https://doi.org/10.1002/ana.26172
doi: 10.1002/ana.26172
pubmed: 34288044
pmcid: 8427115
Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L, Hassan-Smith G, Jones M, Hutchcroft C, Hobson E, Warcel D, White D, Ferdinand P, Webb A, Solomon T, Scully M, Werring DJ, Roffe C (2021) CVT After Immunisation Against COVID-19 (CAIAC) collaborators: cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet 398(10306):1147–1156. https://doi.org/10.1016/S0140-6736(21)01608-1
doi: 10.1016/S0140-6736(21)01608-1
pubmed: 34370972
pmcid: 8346241
Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, di Minno M, Maino A, Martinelli I, Masuhr F, de Sousa DA, Stam J (2017) European stroke organization: European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur Stroke J. 2(3):195–221. https://doi.org/10.1177/2396987317719364
doi: 10.1177/2396987317719364
pubmed: 31008314
pmcid: 6454824
Rapporterade misstänkta biverkningar - coronavaccin | Läkemedelsverket (lakemedelsverket.se)
Handlagda covid-vacciner till 2023–05–31 (lakemedelsverket.se)
Coronaviruset klassas som samhällsfarligt av regeringen | SVT Nyheter]. December 27th, 2020, vaccination campaign against COVID-19 starts [Gun-Britt Johnsson, 91, blev första svensk att vaccineras - DN.SE
Hälften av alla vuxna har fått två doser coronvaccin—Dagens Medicin]. February 2nd, 2022, public emergency measures are suspended [Februari—Folkhälsomyndigheten (folkhalsomyndigheten.se)
Torkzad MR, Thorisson A, Chabok A, Nikberg M, Andersson RE, Labruto F (2022) Impact of COVID-19 on the incidence of CT-diagnosed appendicitis and its complications in the UK and Sweden. Int J Colorectal Dis. 37(6):1375–1383. https://doi.org/10.1007/s00384-022-04181-z
doi: 10.1007/s00384-022-04181-z
pubmed: 35575916
pmcid: 9108134
Ostovan VR, Foroughi R, Rostami M, Almasi-Dooghaee M, Esmaili M, Bidaki AA, Behzadi Z, Farzadfard F, Marbooti H, Rahimi-Jaberi A, Poursadeghfard M, Fadakar N, Bayat M, Owjfard M, Salehi MS, Zafarmand SS, Mardi F, Safari A, Shahjouei S, Mowla A, Azarpazhooh MR et al (2021) Cerebral venous sinus thrombosis associated with COVID-19: a case series and literature review. J Neurol 268(10):3549–3560. https://doi.org/10.1007/s00415-021-10450-8
doi: 10.1007/s00415-021-10450-8
pubmed: 33616740
pmcid: 7897893
Abdalkader M, Shaikh SP, Siegler JE, Cervantes-Arslanian AM, Tiu C, Radu RA, Tiu VE, Jillella DV, Mansour OY, Vera V, Chamorro Á, Blasco J, López A, Farooqui M, Thau L, Smith A, Gutierrez SO, Nguyen TN, Jovin TG (2021) Cerebral venous sinus thrombosis in COVID-19 patients: a multicenter study and review of literature. J Stroke Cerebrovasc Dis. 30(6):105733. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105733
doi: 10.1016/j.jstrokecerebrovasdis.2021.105733
pubmed: 33743411
pmcid: 7931726
Ghosh R, Roy D, Mandal A, Pal SK, Chandra Swaika B, Naga D, Pandit A, Ray BK, Benito-León J (2021) Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr. 15(3):1039–1045. https://doi.org/10.1016/j.dsx.2021.04.026
doi: 10.1016/j.dsx.2021.04.026
pubmed: 34015627
pmcid: 8128714
Kristoffersen ES, Harper CE, Vetvik KG, Faiz KW (2018) Cerebral venous thrombosis—epidemiology, diagnosis and treatment. Tidsskr Nor Laegeforen. https://doi.org/10.4045/tidsskr.17.1047 . (PMID: 30132621)
doi: 10.4045/tidsskr.17.1047
pubmed: 30539605
de Gregorio C, Colarusso L, Calcaterra G, Bassareo PP, Ieni A, Mazzeo AT, Ferrazzo G, Noto A, Koniari I, Mehta JL, Kounis NG (2022) Cerebral venous sinus thrombosis following COVID-19 vaccination: analysis of 552 worldwide cases. Vaccines (Basel) 10(2):232. https://doi.org/10.3390/vaccines10020232.PMID:35214690;PMCID:PMC8874972
doi: 10.3390/vaccines10020232.PMID:35214690;PMCID:PMC8874972
pubmed: 35214690
Domingo RA, Ramos-Fresnedo A, Perez-Vega C, Tripathi S, Pullen MW, Martinez JL, Erben YM, Meschia J, Tawk RG (2022) Cerebral venous thrombosis during the COVID-19 pandemic: a multi-center experience. Clin Neurol Neurosurg. 217:107256. https://doi.org/10.1016/j.clineuro.2022.107256
doi: 10.1016/j.clineuro.2022.107256
pubmed: 35462303
pmcid: 9017058